

On-line Table 1: Imaging protocol for each study center

	AH	MSU	PLA	UW
Scanner				
Manufacturer	GE ^a	GE ^a	GE ^a	GE ^a
Type	Signa Excite	Signa Excite	Signa Excite	Signa Horizon EchoSpeed
Field strength	3T	3T	3T	1.5T
3D TOF				
Sequence	SPGR	SPGR	SPGR	SPGR
TR/TE (ms)	21/2.9	23.5/3.5	29/2.1	23/3.6
Flip angle	15°	20°	20°	25°
2D PD				
Sequence	FSE	—	FSE	FSE
TR/TE (ms)	3000/15	—	3000/13	3000/9
Blood suppression ^b	MDIR	—	MDIR	MDIR
2D T2WI				
Sequence	FSE	FSE	FSE	FSE
TR/TE (ms)	3000/75	4000/52	3000/66	3000/54
Blood suppression ^b	MDIR	MDIR	MDIR	MDIR
2D T1WI				
Sequence	FSE	FSE	FSE	FSE
TR/TE (ms)	800/11	800/11	800/8.8	800/11
Blood suppression ^b	QIR	QIR	QIR	QIR
FOV (mm)	140	160	140	160
Matrix size	256 × 256	256 × 256	256 × 256	256 × 256
Resolution (mm ²)	0.55 × 0.55	0.62 × 0.62	0.55 × 0.55	0.62 × 0.62
Pixel size (mm ²)	0.28 × 0.28	0.31 × 0.31	0.28 × 0.28	0.31 × 0.31
Section thickness (mm)	2	2	2	2
No. of sections	18	18	12	12
Contrast agent ^c	Magnevist	Multihance	Omniscan	Omniscan
3D MRA	Yes	Yes	No	No
Sequence	FSPGR	FSPGR	—	—
<i>k</i> -space ordering	Elliptic centric	Elliptic centric	—	—
TR/TE (ms)	2.5/1.2	5.4/1.3	—	—
Flip angle	40°	30°	—	—
FOV (mm)	320	320	—	—
Matrix size	192 × 320	192 × 320	—	—

Note: — indicates not applicable.

^a GE Healthcare, Milwaukee, Wisconsin.

^b QIR³⁵; MDIR³⁶

^c Contrast agents used were the following: Magnevist (gadopentetate dimeglumine; Bayer Schering Pharma, Berlin, Germany); Multihance (gadobenate dimeglumine; Bracco Diagnostic, Princeton, New Jersey); Omniscan (gadolinium-DTPA-BMA, GE Healthcare).

On-line Table 2: Results of univariate analysis (training set, $n = 196$)

	Univariate		Present	Absent	Multivariate	
	OR	P Value			OR	P Value
IPH (no.)			47	149		
Male sex	3.0 (1.2, 7.4)	.022	87.2%	69.8%	—	—
Presence of LRNC	Inf (13.0, Inf) ^b	<.001 ^a	100.0%	47.0%	—	—
Max wall area (per 10-mm ² increase)	1.5 (1.3, 1.9)	<.001	75.8 ± 26.1 (30.6–153.9)	56.4 ± 17.6 (24.2–127.2)	—	—
Max TVA (per 10-mm ² increase)	1.1 (1.0, 1.2)	.034	122.8 ± 38.2 (45.8–243.2)	109.9 ± 34.4 (50.4–263.0)	—	—
Max wall thickness (per 1-mm increase)	1.9 (1.5, 2.4)	<.001	5.35 ± 2.02 (2.74–12.92)	3.49 ± 1.46 (1.16–9.92)	—	—
Max NWI (per 0.10 increase)	3.1 (2.1, 4.6)	<.001	0.815 ± 0.092 (0.470–0.986)	0.659 ± 0.131 (0.398–0.983)	—	—
Max percentage LRNC (per 10% increase)	3.3 (2.3, 4.7)	<.001	49.9 ± 14.3 (18.4–84.9)	12.6 ± 16.5 (0.0–64.7)	3.3 (2.3, 4.7)	<.001
Fibrous cap rupture (No.)			14	182		
Male sex	Inf (1.2, Inf) ^b	.023 ^a	100%	72.0%	—	—
Presence of LRNC	Inf (2.4, Inf) ^b	.001 ^a	100.0%	56.6%	—	—
Max wall area (per 10-mm ² increase)	1.415 (1.2, 1.8)	.001	82.6 ± 28.2 (51.9–153.9)	59.4 ± 20.1 (24.2–153.2)	—	—
Max wall thickness (per 1-mm increase)	1.6 (1.3, 2.1)	<.001	6.05 ± 2.34 (3.79–12.92)	3.77 ± 1.64 (1.16–11.80)	—	—
Max NWI (per 0.10 increase)	4.2 (2.1, 8.5)	<.001	0.863 ± 0.061 (0.752–0.986)	0.683 ± 0.135 (0.398–0.983)	—	—
Max percentage LRNC (per 10% increase)	2.5 (1.6, 3.8)	<.001	56.7 ± 15.4 (34.1–84.9)	18.8 ± 20.7 (0.00–74.7)	2.5 (1.6, 3.8)	<.001
MRA stenosis (per 10% increase)	1.5 (1.0, 2.3)	.073	71.4 ± 16.7 (5) (58–99)	45.9 ± 29.3 (68) 0–99)	—	—
LRNC (No.)			117	79		
Male sex	2.0 (1.1, 3.8)	.034	79.5%	65.8%	—	—
Max wall area (per 10-mm ² increase)	1.7 (1.4, 2.1)	<.001	68.0 ± 22.7 (25.2–153.9)	50.8 ± 14.8 (24.2–87.4)	—	—
Max TVA (per 10-mm ² increase)	1.2 (1.1, 1.3)	.002	119.6 ± 35.0 (45.8–263.0)	103.2 ± 34.7 (50.4–200.2)	1.2 (1.0, 1.3)	.010
Max wall thickness (per 1-mm increase)	2.2 (1.6, 2.9)	<.001	4.5 ± 1.9 (2.1–12.9)	3.1 ± 1.2 (1.2–7.5)	1.5 (1.0, 2.3)	.040
Max NWI (per 0.10 increase)	1.8 (1.4, 2.3)	<.001	0.739 ± 0.134 (0.430–0.986)	0.633 ± 0.124 (0.398–0.902)	1.5 (1.0, 2.2)	.039

Note:— — indicates not applicable.

^a χ^2 test.

^b Positive OR that cannot be estimated due to zero in 1 of the cells (Inf estimated OR). One-sided 95% CI presented.